Literature DB >> 28952228

Differentiation between progression and pseudoprogresion by arterial spin labeling MRI in patients with glioblastoma multiforme.

Marija Jovanovic1, Sandra Radenkovic, Tatjana Stosic-Opincal, Slobodan Lavrnic, Svetlana Gavrilovic, Biljana Lazovic-Popovic, Ivan Soldatovic, Ruzica Maksimovic.   

Abstract

PURPOSE: To compare arterial spin labeling (ASL) perfusion technique with the clinically established dynamic susceptibility contrast-enhanced (DSC) perfusion weighted-imaging (PWI), and to determine its value in routine MRI evaluation of disease progression in patients with glioblastoma multiforme (GBM).
METHODS: A prospective intraindividual study was performed in 31 patients with histologically proven GBM who had clinical and/or radiological deterioration after treatment, including surgery, radiotherapy and therapy with temozolomide. Conventional brain protocol with ASL and DSC techniques was performed on 3T MRI unit. Cerebral blood flow (CBF) and cerebral blood volume (CBV) maps were analyzed by means of regions of interest (ROI). Each ROI average value was normalized to the contralateral normal brain parenchyma ROI value. Neuroradiologists analyzed CBF and CBV maps separately, and classified patients into progression or pseudoprogression group. Radiological diagnosis was confirmed by clinical-radiological follow-up for at least three months after patient deterioration.
RESULTS: High linear correlation existed between DSC-PWI and ASL in the tumor ROI (r=0.733; p<0.001). 92% of ASL CBF maps were informative. ASL detected all lesions as well as DSC MRI. Both techniques provided perfusion values closely correlated.
CONCLUSION: ASL allows distinction between GBM progression and pseudoprogression, and it can be used as reliable alternative to DSC-PWI.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28952228

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  6 in total

Review 1.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

2.  Hybrid [18F]-F-DOPA PET/MRI Interpretation Criteria and Scores for Glioma Follow-up After Radiotherapy.

Authors:  Marc Bertaux; Arnaud Berenbaum; Anna-Luisa Di Stefano; Laura Rozenblum; Marine Soret; Sebastien Bergeret; Khé Hoang-Xuan; Laure-Eugenie Tainturier; Brian Sgard; Marie-Odile Habert; Jean-Yves Delattre; Caroline Dehais; Ahmed Idbaih; Nadya Pyatigorskaya; Aurelie Kas
Journal:  Clin Neuroradiol       Date:  2022-02-11       Impact factor: 3.156

3.  Reduction of intratumoral brain perfusion by noninvasive transcranial electrical stimulation.

Authors:  G Sprugnoli; L Monti; L Lippa; F Neri; L Mencarelli; G Ruffini; R Salvador; G Oliveri; B Batani; D Momi; A Cerase; A Pascual-Leone; A Rossi; S Rossi; E Santarnecchi
Journal:  Sci Adv       Date:  2019-08-14       Impact factor: 14.136

Review 4.  Advanced Neuroimaging Approaches to Pediatric Brain Tumors.

Authors:  Rahul M Nikam; Xuyi Yue; Gurcharanjeet Kaur; Vinay Kandula; Abdulhafeez Khair; Heidi H Kecskemethy; Lauren W Averill; Sigrid A Langhans
Journal:  Cancers (Basel)       Date:  2022-07-13       Impact factor: 6.575

5.  Discriminators of pseudoprogression and true progression in high-grade gliomas: A systematic review and meta-analysis.

Authors:  Chris Taylor; Justyna O Ekert; Viktoria Sefcikova; Naomi Fersht; George Samandouras
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

6.  Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression.

Authors:  Jun Zhang; Yulin Wang; Yan Wang; Huafeng Xiao; Xinjing Chen; Yifei Lei; Zhebin Feng; Xiaodong Ma; Lin Ma
Journal:  Quant Imaging Med Surg       Date:  2022-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.